Salt bridge integrates GPCR activation with protein trafficking

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 9, 2010, Pages 4454-4458

  Janovick, Jo Ann ^a   Conn, P Michael ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Constitutive activity; G protein coupled receptor; Hormone action; Receptor; Receptor trafficking

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLUTAMIC ACID; GONADORELIN RECEPTOR; LIGAND; LYSINE; RECEPTOR; SODIUM CHLORIDE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CELL PROTECTION; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TRANSPORT; RECEPTOR DOWN REGULATION;

HUMANS; PROTEIN TRANSPORT; RECEPTORS, G-PROTEIN-COUPLED; SALTS;

EID: 77749264618     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914261107     Document Type: Article

References (31)

1. Tao YX (2008) Constitutive activation of G protein-coupled receptors and diseases: Insights into mechanisms of activation and therapeutics. Pharmacol Ther 120:129-148.
2. Bond RA, Ijzerman AP (2006) Recent developments in constitutive receptor activity and inverse agonism, and theirpotential forGPCR drug discovery. Trends Pharmacol Sci 27:92-96.
3. Seifert R, Wenzel-Seifert K (2002) Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 366:381-416.
4. Janovick JA, et al. (2009) Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor. Mol Endocrinol 23:157-168.
5. Flanagan CA, et al. (2000) Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction. Biochemistry 39:8133-8141.
6. Zhou W, et al. (1995) A locus of the gonadotropin-releasing hormone receptor that differentiates agonist and antagonist binding sites. J Biol Chem 270:18853-18857.
7. Blomenröhr M, et al. (2001) Proper receptor signalling in a mutant catfish gonadotropin-releasing hormone receptor lacking the highly conserved Asp(90) residue. FEBS Lett 501:131-134.
8. Maya-Núñez G, et al. (2002) Molecular basis of hypogonadotropic hypogonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. J Clin Endocrinol Metab 87:2144-2149.
9. Brothers SP, Cornea A, Janovick JA, Conn PM(2004) Human loss-of-function gonadotropinreleasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: Molecular basis of the dominant-negative effect. Mol Endocrinol 18:1787-1797.
10. Janovick JA, et al. (2007) Refolding of misfolded mutant GPCR: Post-translational pharmacoperone action in vitro. Mol Cell Endocrinol 272:77-85.
11. Conn PM, Janovick JA (2009) Drug development and the cellular quality control system. Trends Pharmacol Sci 30:228-233.
12. Janovick JA, et al. (2003) Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther 305:608-614.
13. Janovick JA, Maya-Nunez G, Conn PM (2002) Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific proteinfolding template: Misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87:3255-3262.
14. Leaños-Miranda A, Janovick JA, Conn PM (2002) Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 87:4825-4828.
15. Leaños-MirandaA, Ulloa-Aguirre A, Janovick JA, ConnPM(2005) In vitro coexpression and pharmacological rescue of mutant gonadotropin-releasing hormone receptors causing hypogonadotropic hypogonadisminhumans expressing compound heterozygous alleles. J Clin Endocrinol Metab 90:3001-3008.
16. Leaños-Miranda A, Ulloa-Aguirre A, Ji TH, Janovick JA, Conn PM (2003) Dominantnegative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans. J Clin Endocrinol Metab 88:3360-3367.
17. Janovick JA, et al. (2006) Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy. J Biol Chem 281:8417-8425.
18. Grant G, et al. (1973) Recent Studies of Hypothalamic Function Int. Symp, eds Lederis K, Cooper KE (Karger, Calgary), pp 180-195.
19. Conn PM, Janovick JA (2009) Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 299:137-145.
20. Costa T, Herz A (1989) Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
21. Brothers SP, Janovick JA, Conn PM (2003) Unexpected effects of epitope and chimeric tags on gonadotropin-releasing hormone receptors: implications for understanding the molecular etiology of hypogonadotropic hypogonadism. J Clin Endocrinol Metab 88:6107-6112.
22. Milligan G, Bond RA (1997) Inverse agonism and the regulation of receptor number. Trends Pharmacol Sci 18:468-474.
23. Huckle WR, Conn PM (1987) Use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover. Methods Enzymol 141:149-155.
24. Conn PM, Leaños-Miranda A, Janovick JA (2002) Protein origami: Therapeutic rescue of misfolded gene products. Mol Interv 2:308-316.
25. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM (2004) Pharmacologic rescue of conformationally-defective proteins: Implications for the treatment of human disease. Traffic 5:821-837.
26. Castro-Fernández C, Maya-Núñez G, Conn PM (2005) Beyond the signal sequence: protein routing in health and disease. Endocr Rev 26:479-503.
27. Cook JV, Eidne KA (1997) An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releasing hormone receptor is essential for binding and activation. Endocrinology 138:2800-2806.
28. Knollman PE, Janovick JA, Brothers SP, Conn PM (2005) Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropinreleasing hormone receptor mutants. J Biol Chem 280:24506-24514.
29. Janovick JA, Ulloa-Aguirre A, Conn PM (2003) Evolved regulation of gonadotropinreleasing hormone receptor cell surface expression. Endocrine 22:317-327.
30. Ulloa-Aguirre A, Janovick JA, Leaños-Miranda A, Conn PM (2003) Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: the case of hypogonadotropic hypogonadism due to gonadotropin-releasing hormone resistance. Expert Opin Ther Targets 7:175-185.
31. Brothers SP, et al. (2002) Conserved mammalian gonadotropin-releasing hormone receptor carboxyl terminal amino acids regulate ligand binding, effector coupling and internalization.Mol Cell Endocrinol 190:19-27.